INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 140 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2017. The put-call ratio across all filers is 1.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $8,821,000 | -8.2% | 609,166 | 0.0% | 0.08% | -2.6% |
| Q3 2017 | $9,613,000 | +27.1% | 609,166 | 0.0% | 0.08% | +18.2% |
| Q2 2017 | $7,566,000 | -23.6% | 609,166 | 0.0% | 0.07% | -18.5% |
| Q1 2017 | $9,899,000 | +7.7% | 609,166 | 0.0% | 0.08% | -10.0% |
| Q4 2016 | $9,192,000 | -1.0% | 609,166 | 0.0% | 0.09% | +7.1% |
| Q3 2016 | $9,284,000 | -60.7% | 609,166 | 0.0% | 0.08% | -66.1% |
| Q2 2016 | $23,648,000 | +39.6% | 609,166 | 0.0% | 0.25% | +38.5% |
| Q1 2016 | $16,935,000 | -48.3% | 609,166 | 0.0% | 0.18% | -33.9% |
| Q4 2015 | $32,767,000 | +34.3% | 609,166 | 0.0% | 0.27% | +20.4% |
| Q3 2015 | $24,391,000 | +632.9% | 609,166 | +484.8% | 0.22% | +675.9% |
| Q2 2015 | $3,328,000 | +33.8% | 104,166 | 0.0% | 0.03% | +38.1% |
| Q1 2015 | $2,487,000 | – | 104,166 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |